Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.
Source: MarketWatch
Wednesday, 04. February 2026
Share:
04. February 2026 11:41
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
